ELCC 2015: Exhibitor Profiles
AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world’s most complex and serious diseases. In 2013, AbbVie employed approximately 21,000 people worldwide and markets medicines in more than 170 countries.
Follow @abbvie on Twitter.
Booth Number: 16
AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
Booth Number: 14
Boehringer Ingelheim is committed to delivering novel anti-cancer agents that address unmet needs across a broad range of solid and liquid tumours. For lung cancer BI now has two approved agents for specific NSCLC sub-types. The late stage portfolio is supported by a strong early pipeline and was recently supplemented with a major in-licensing deal of a novel therapeutic vaccine.
Booth Number: 12
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. Our medicines are helping millions of people around the world in their fight against cancer, cardiovascular disease, hepatitis B, HIV/AIDS and rheumatoid arthritis.
Booth Number: 3
In our pursuit to improve the lives of people living with cancer,
Clovis Oncology is committed to realizing the promise of personalized medicines for cancer. We seek to develop targeted therapies in combination with companion diagnostics to better serve patients and ensure the right drug gets to the right patient.
Booth Number: 13
Helsinn is a private pharmaceutical group focused on building quality cancer care headquartered in Switzerland with subsidiaries in Switzerland, Ireland, US, and representative office in China. Helsinn’s business model is focused on developing, registering and licensing pharmaceuticals, medical devices and nutritional supplements through partner companies, and marketing pharmaceutical products in the US through its subsidiary Helsinn Therapeutics (U.S.), Inc.
Booth Number: 17
For more than four decades,
Lilly Oncology has been dedicated to delivering innovative solutions that improve the care of people living with cancer. Lilly Oncology is committed to developing novel treatment approaches that accelerate the pace and progress of cancer care. We also understand cancer care is complex and we’re working to provide support services that are meaningful for you and your patients.
Booth Number: 2
MSD is a global healthcare leader working to help the world be well. MSD is known as Merck in the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships.
Booth Number: 11
Novartis Oncology has emerged as a global leader in oncology through targeted research and open partnership in the pursuit of new therapies capable of transforming outcomes for people with cancer. We offer a wide range of innovative therapies to help physicians meet patient needs, with one of the broadest and most comprehensive oncology pipelines in the industry. Our research is driven by a distinctive scientific and clinical strategy, focusing on unmet medical needs and disease pathways.
Booth Number: 15
Otsuka Pharmaceutical Europe
Otsuka Pharmaceutical is a global healthcare company with the corporate philosophy: 'Otsuka-people creating new products for better health worldwide.' Otsuka is committed to focusing its research and development on innovative products and medical devices that address unmet medical needs. Come and visit Otsuka Europe at Stand 143 to learn more about Otsuka’s commitment to innovation and education.
Booth Number: 18
Pfizer Oncology is committed to the discovery, investigation and development of innovative treatment options to improve the outlook for cancer patients worldwide. Our strong pipeline of biologics and small molecules is studied with precise focus on identifying and translating the best scientific breakthroughs into clinical application for patients across a wide range of cancers.
Booth Number: 10
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients. Founded in 1896, Roche has been making important contributions to global health for more than a century. Twenty-four medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and chemotherapy.
In 2014, the Roche Group employed 88,500 people worldwide, invested 8.9 billion Swiss francs in R&D and posted sales of 47.5 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.
Booth Number: 19
Wisepress Medical Bookshop
Wisepress.com, Europe’s leading conference bookseller, has a range of books and journals relevant to the themes of the meeting. In addition to attending 200 conferences per year, Wisepress has a comprehensive medical and scientific bookshop online with great offers. Follow us on Twitter for the latest news @WisepressBooks.
Booth Number: 30
European Society for Medical Oncology - ESMO
ESMO is the leading European professional organization committed to advancing the specialty of medical oncology and promoting a multidisciplinary approach to cancer treatment. ESMO is committed to good science that leads to better medicine and determines best practice. ESMO represents a community of over 10,000 oncology professionals from over 120 countries.
Booth Number: 4
European SocieTy for Radiotherapy and Oncology - ESTRO
ESTRO is a not-for-profit organisation that advances all aspects of radiation oncology in order to improve patients’ care in the multimodality treatment of cancer. With 5,000 members around the world, ESTRO’s mission is to promote innovation, dissemination of science and education, hence supporting all the radiation oncology professionals in their daily practice.
Booth Number: 7
European Society of Thoracic Surgeons - ESTS
ESTS is the largest international general thoracic surgery organization with over 1350 members from all Continents. Our mission is to improve quality in our specialty: from clinical and surgical management of patients to education, training and credentialing of thoracic surgeons worldwide.
Booth Number: 8
International Association for the Study of Lung Cancer - IASLC
The International Association for the Study of Lung Cancer (
IASLC) is the only global organization dedicated to the study of lung cancer. Founded in 1974, the association's membership includes nearly 4,000 lung cancer specialists in 80 countries. IASLC members work to enhance the understanding of lung cancer among scientists, members of the medical community and the public. IASLC publishes the Journal of Thoracic Oncology, a valuable resource for medical specialists and scientists who focus on the detection, prevention, diagnosis and treatment of lung cancer.
Booth Number: 5
Lung Cancer Europe - LuCE
Lung Cancer Europe is the voice of lung cancer patients, their families and survivors at a European level. LuCE aims at increasing the survival rates and the improvement of health related quality of life of lung cancer patients in Europe. It raises awareness about inequities in the access to treatment and care in Europe and it advocates European policies that will lead to improvements in lung cancer prevention, early detection, treatment and care. LuCE provides a European platform for existing lung cancer patient advocacies and supports the establishment of new national lung cancer patient groups in different European countries.
Booth Number: 6